S&P 500   4,303.18 (+0.14%)
DOW   34,137.68 (+0.66%)
QQQ   331.39 (-0.50%)
AAPL   172.35 (-0.49%)
MSFT   292.07 (-0.48%)
META   178.83 (-1.14%)
GOOGL   121.32 (-0.62%)
AMZN   144.29 (+0.78%)
TSLA   917.32 (-1.15%)
NVDA   188.36 (-1.03%)
NIO   20.81 (-2.30%)
BABA   92.52 (-1.78%)
AMD   99.88 (-1.12%)
MU   63.61 (-1.68%)
T   18.60 (+1.14%)
CGC   3.78 (-1.05%)
F   16.42 (+0.61%)
GE   80.76 (+1.19%)
DIS   125.14 (+0.71%)
AMC   24.80 (+2.44%)
PYPL   102.08 (+0.56%)
PFE   49.78 (+0.06%)
NFLX   246.18 (-1.18%)
S&P 500   4,303.18 (+0.14%)
DOW   34,137.68 (+0.66%)
QQQ   331.39 (-0.50%)
AAPL   172.35 (-0.49%)
MSFT   292.07 (-0.48%)
META   178.83 (-1.14%)
GOOGL   121.32 (-0.62%)
AMZN   144.29 (+0.78%)
TSLA   917.32 (-1.15%)
NVDA   188.36 (-1.03%)
NIO   20.81 (-2.30%)
BABA   92.52 (-1.78%)
AMD   99.88 (-1.12%)
MU   63.61 (-1.68%)
T   18.60 (+1.14%)
CGC   3.78 (-1.05%)
F   16.42 (+0.61%)
GE   80.76 (+1.19%)
DIS   125.14 (+0.71%)
AMC   24.80 (+2.44%)
PYPL   102.08 (+0.56%)
PFE   49.78 (+0.06%)
NFLX   246.18 (-1.18%)
S&P 500   4,303.18 (+0.14%)
DOW   34,137.68 (+0.66%)
QQQ   331.39 (-0.50%)
AAPL   172.35 (-0.49%)
MSFT   292.07 (-0.48%)
META   178.83 (-1.14%)
GOOGL   121.32 (-0.62%)
AMZN   144.29 (+0.78%)
TSLA   917.32 (-1.15%)
NVDA   188.36 (-1.03%)
NIO   20.81 (-2.30%)
BABA   92.52 (-1.78%)
AMD   99.88 (-1.12%)
MU   63.61 (-1.68%)
T   18.60 (+1.14%)
CGC   3.78 (-1.05%)
F   16.42 (+0.61%)
GE   80.76 (+1.19%)
DIS   125.14 (+0.71%)
AMC   24.80 (+2.44%)
PYPL   102.08 (+0.56%)
PFE   49.78 (+0.06%)
NFLX   246.18 (-1.18%)
S&P 500   4,303.18 (+0.14%)
DOW   34,137.68 (+0.66%)
QQQ   331.39 (-0.50%)
AAPL   172.35 (-0.49%)
MSFT   292.07 (-0.48%)
META   178.83 (-1.14%)
GOOGL   121.32 (-0.62%)
AMZN   144.29 (+0.78%)
TSLA   917.32 (-1.15%)
NVDA   188.36 (-1.03%)
NIO   20.81 (-2.30%)
BABA   92.52 (-1.78%)
AMD   99.88 (-1.12%)
MU   63.61 (-1.68%)
T   18.60 (+1.14%)
CGC   3.78 (-1.05%)
F   16.42 (+0.61%)
GE   80.76 (+1.19%)
DIS   125.14 (+0.71%)
AMC   24.80 (+2.44%)
PYPL   102.08 (+0.56%)
PFE   49.78 (+0.06%)
NFLX   246.18 (-1.18%)
NYSE:EW

Edwards Lifesciences - EW Stock Forecast, Price & News

$101.98
-2.76 (-2.64%)
(As of 08/16/2022 03:22 PM ET)
Add
Compare
Today's Range
$101.91
$103.89
50-Day Range
$86.50
$107.29
52-Week Range
$85.58
$131.73
Volume
59,210 shs
Average Volume
2.49 million shs
Market Capitalization
$63.22 billion
P/E Ratio
44.15
Dividend Yield
N/A
Price Target
$125.90

Edwards Lifesciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
22.5% Upside
$125.90 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.38mentions of Edwards Lifesciences in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$9.74 M Sold Last Quarter
Proj. Earnings Growth
8.37%
From $2.51 to $2.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Medical Sector

106th out of 1,124 stocks

Surgical Appliances & Supplies Industry

6th out of 23 stocks

EW stock logo

About Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $104.74 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.37 and a quick ratio of 2.60. Edwards Lifesciences has a 1-year low of $85.58 and a 1-year high of $131.73. The firm has a market capitalization of $64.93 billion, a P/E ratio of 45.34, a price-to-earnings-growth ratio of 3.09 and a beta of 1.12. The company's 50-day moving average is $97.97 and its 200 day moving average is $105.03.

Edwards Lifesciences (NYSE:EW - Get Rating) last posted its quarterly earnings data on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $0.64 by ($0.01). Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. The firm had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same period last year, the company earned $0.64 earnings per share. The business's revenue for the quarter was down .2% compared to the same quarter last year. Research analysts forecast that Edwards Lifesciences will post 2.51 EPS for the current year.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Stifel Nicolaus decreased their target price on shares of Edwards Lifesciences from $128.00 to $115.00 in a research note on Monday, July 18th. Citigroup reduced their price objective on Edwards Lifesciences from $134.00 to $115.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th. Truist Financial reduced their price objective on Edwards Lifesciences from $140.00 to $120.00 and set a "buy" rating for the company in a research note on Wednesday, July 20th. Canaccord Genuity Group lowered Edwards Lifesciences from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $115.00 to $106.00 in a research note on Friday, July 29th. Finally, StockNews.com raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Friday, August 5th. Three research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $126.19.

Insider Transactions at Edwards Lifesciences

In other news, CEO Michael A. Mussallem sold 19,875 shares of the firm's stock in a transaction that occurred on Tuesday, June 14th. The shares were sold at an average price of $86.96, for a total transaction of $1,728,330.00. Following the transaction, the chief executive officer now directly owns 157,353 shares of the company's stock, valued at $13,683,416.88. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Michael A. Mussallem sold 19,875 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, June 14th. The shares were sold at an average price of $86.96, for a total transaction of $1,728,330.00. Following the transaction, the chief executive officer now directly owns 157,353 shares of the company's stock, valued at $13,683,416.88. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Bernard J. Zovighian sold 4,811 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $103.66, for a total transaction of $498,708.26. Following the transaction, the vice president now directly owns 21,247 shares in the company, valued at $2,202,464.02. The disclosure for this sale can be found here. Over the last three months, insiders have sold 100,937 shares of company stock valued at $9,738,239. 1.29% of the stock is currently owned by company insiders.

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

Edwards Lifesciences (NYSE:EW) Raised to "Buy" at StockNews.com
Edwards Lifesciences Corp. Q2 Profit Decreases, misses estimates
EW June 2023 Options Begin Trading
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Company Calendar

Last Earnings
7/28/2022
Today
8/16/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
15,700
Year Founded
1958

Price Target and Rating

Average Stock Price Forecast
$125.90
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$106.00
Forecasted Upside/Downside
+23.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
20 Analysts

Profitability

Net Income
$1.50 billion
Pretax Margin
31.15%

Debt

Sales & Book Value

Annual Sales
$5.23 billion
Cash Flow
$2.40 per share
Book Value
$9.35 per share

Miscellaneous

Free Float
611,946,000
Market Cap
$63.22 billion
Optionable
Optionable
Beta
1.12

Social Links















EW Stock - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EW shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price forecast for 2022?

20 brokers have issued 12-month price targets for Edwards Lifesciences' shares. Their EW share price forecasts range from $106.00 to $144.00. On average, they anticipate the company's share price to reach $125.90 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2022?

Edwards Lifesciences' stock was trading at $129.55 at the start of the year. Since then, EW stock has decreased by 19.2% and is now trading at $104.74.
View the best growth stocks for 2022 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a decline in short interest in July. As of July 31st, there was short interest totaling 5,540,000 shares, a decline of 16.8% from the July 15th total of 6,660,000 shares. Based on an average daily trading volume, of 2,680,000 shares, the short-interest ratio is currently 2.1 days. Currently, 0.9% of the shares of the company are sold short.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) posted its earnings results on Thursday, July, 28th. The medical research company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $0.64 by $0.01. The medical research company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 27.18% and a trailing twelve-month return on equity of 24.77%. The firm's revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 earnings per share.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Shares of Edwards Lifesciences split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $2.50-$2.50 for the period, compared to the consensus earnings per share estimate of $2.56. The company issued revenue guidance of $5.35 billion-$5.55 billion, compared to the consensus revenue estimate of $5.71 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional investors include Bank of Nova Scotia (93.89%), State Street Corp (4.34%), Brown Advisory Inc. (2.57%), Sands Capital Management LLC (1.89%), FMR LLC (1.43%) and Northern Trust Corp (1.06%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, Scott B Ullem and William J Phd Link.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $104.74.

How much money does Edwards Lifesciences make?

Edwards Lifesciences (NYSE:EW) has a market capitalization of $64.93 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.31 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

The company employs 15,700 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.

This page (NYSE:EW) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.